The Trump administration is re-evaluating its stance on federal law 922(g)(3), which impacts medical cannabis gun rights.

The global medical cannabis market is set to reach US$148.9 billion by 2031, fueled by regulatory reforms and expanding ...

The US Justice Department's Schedule III reclassification for medical cannabis products is revitalizing investor interest.

A UC Berkeley study reveals licensed cannabis farms are the most effective deterrent to unlicensed cultivation in California, ...

Discover how industrial hemp construction, particularly hempcrete, is revolutionizing the building industry. Learn about its ...

The US House has passed the 2026 Farm Bill, retaining a ban on intoxicating hemp products. This decision creates significant ...

Explore how the US reclassification of cannabis is poised to drive IPOs and private funding for companies developing cannabis ...

Medical cannabis businesses face a complex 60-day window for DEA registration, navigating potential legal admissions of past ...

Explore the potential for Nebraska medical cannabis laws to gain protection from federal interference. This analysis delves ...

Understanding true cannabis manufacturing costs is critical for operators navigating volatile markets. Learn how to ...

The U.S. House passed the Farm Bill, including key provisions to reduce regulatory burdens for industrial hemp producers.

Vireo Growth's acquisition of Fluent via a debt-for-stock deal significantly reshapes the medical cannabis market in Florida, ...